CLINICAL_TRIALS
trial_result
· 2026-02-27
Clinical Trial Update: Anlotinib and Benmelstobart in DTC [Phase 2]
Summary
A Phase 2 clinical trial evaluating the combination of Anlotinib and Benmelstobart for differentiated thyroid cancer is not yet recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Fudan University | Conditions: Thyroid Cancer | Phase 2 | Status: NOT_YET_RECRUITING